A Phase I/II Clinical Trial with Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -vaccination
Latest Information Update: 06 Mar 2025
At a glance
- Drugs SCB 2019 (Primary) ; Varicella zoster virus vaccine live
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Ab&B Biotech
- 04 Mar 2025 New trial record